-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Kymera Therapeutics, Raises Price Target to $152

Benzinga·09/22/2026 10:45:02
Stifel analyst Alex Thompson maintains Kymera Therapeutics (NASDAQ:KYMR) with a Buy and raises the price target from $132 to $152.